Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors

Inclusion Criteria: * The subjects voluntarily joined this study, signed an informed consent form, and had good compliance; * Age between 18 and 75 years old (calculated based on the date of signing the informed consent form); * Eastern Cooperative Oncology Group (ECOG) score from 0 to 1; * Expected survival is greater than 12 weeks; * Advanced solid tumors with HER2 expression confirmed by histopathological/cytological examination. HER2 expression includes HER2 positive (including Immunohistochemistry (IHC) 3+, IHC 2+and Fish positive), HER2 low expression (including IHC 1+ IHC 2+and Fish negative, HC 0 but with HER2 expression); * Confirm the presence of at least one measurable lesion according to RECIST 1.1 criteria; * The laboratory inspection meets the following standards: * Blood routine: Hemoglobin (HGB) levels in the past 14 days without the use of growth factors or blood transfusions * 90g/L ； Neutrophil absolute value (NEUT) ≥ 1.5 × 10 9/L; Platelet count (PLT) * 100×10 9 /L ； * Liver function: For patients without liver metastasis, total bilirubin (TBIL) is ≤ 1.5 times the upper limit of normal (ULN), For patients with liver metastasis, total bilirubin (TBIL) ≤ 3.0 times the upper limit of normal (ULN); Alanine group Transferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN. If accompanied by liver transformation Move, then ALT and AST ≤ 5 × ULN; * Renal function: Serum creatinine (CR) ≤ 1.5 × ULN or creatinine clearance rate (CCr) ≥ 60 ml…